Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TA
Tarsus Pharmaceuticals, Inc. Common Stock
TARS
Mkt Cap
$3.19B
Volume
841.76K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TA
TARS
TA
Tarsus Pharmaceuticals, Inc. Common Stock
TARS
News
·
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Mkt Cap
$3.32B
Volume
841.76K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Insider
Filings
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Tarsus Pharmaceuticals announced a webcast on August 6, 2026 to report Q2 2026 financial results and provide a corporate update. The company also announced an executive leadership transition with Chief Commercial Officer Aziz Mottiwala departing, while advancing its eye care strategy through the acquisition of iRenix Medical and the late-stage asset IRX-101 for ocular antiseptic use.
GlobeNewswire Inc. · Aug 6, 2026
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals reported first quarter 2026 XDEMVY net product sales exceeding $145 million, representing an 85% year-over-year increase. The company reaffirmed its full-year 2026 guidance of $670-700 million in XDEMVY sales and announced participation in three upcoming investor conferences in May.
GlobeNewswire Inc. · May 7, 2026
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade
Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares worth approximately $839,000 between March 17-19, 2026. The sale was a non-discretionary, tax-withholding-driven transaction tied to RSU vesting rather than a reflection of insider sentiment. Despite the insider sale, the company continues to show strong commercial execution with $451.4 million in net product sales in 2025 (more than double the prior year), driven by rapid adoption of XDEMVY, with gross margins around 93% and narrowing net losses.
The Motley Fool · Mar 24, 2026
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Tarsus Pharmaceuticals will host a live webcast on November 4, 2025, to report its third quarter 2025 financial results and provide a corporate update. The company has FDA-approved XDEMVY for Demodex blepharitis and is developing additional treatments for eye care and infectious disease prevention.
GlobeNewswire Inc. · Oct 28, 2025
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase
Capricorn Fund Managers Ltd acquired 484,500 shares of Phreesia, valued at $11.4 million, representing 3.8% of their reportable assets under management. The investment comes as Phreesia reaches a milestone of first quarterly net income and plans to expand payment solutions.
The Motley Fool · Oct 27, 2025
Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight
DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development.
GlobeNewswire Inc. · Oct 1, 2025
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals plans to participate in two upcoming healthcare investment conferences in September 2025, showcasing its eye care and infectious disease prevention pipeline, including its FDA-approved XDEMVY® treatment for Demodex blepharitis.
GlobeNewswire Inc. · Aug 27, 2025
3 Biotech Catalysts Present Major Opportunity
Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.
Investing.com · Aug 27, 2025
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Tarsus Pharmaceuticals will host a live webcast on August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update, discussing its eye care and infectious disease prevention pipeline.
GlobeNewswire Inc. · Jul 30, 2025
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals announced plans to participate in several upcoming investor conferences, including the William Blair 45th Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 46th Annual Global Healthcare Conference.
GlobeNewswire Inc. · May 29, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TA
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
TARS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any TARS yet.
Related Tickers
Earnings